Table 4 Univariate analysis of overall survival according to the VEGF and VEGFR immunohistochemical score in GBMs

VEGF-A

62 / 8 (11.4%)^a

57/62 (91.9%)

1

5 (7.1%)

0.96 (0.29–3.20)

8 (11.4%)

0.78 (0.26–2.32)

20 (28.6%)

0.86 (0.30–2.47)

29 (41.4%)

VEGF-C

56 /14 (20%)^a

53/56 (94.6)

1

3 (4.3%)

1.149 (0.35–6.34)

5 (7.1%)

1.19 (0.31–4.59)

9 (12.9%)

1.11 (0.34–3.63)

39 (55.7%)

VEGF-D

63 /7 (10.0%)^a

55/63 (87.3)

1

8 (11.4%)

4.27 (1.30–13.95)

6 (8.6%)

1.45 (0.52–4.06)

11 (15.7%)

1.07 (0.45–2.57)

38 (54.3%)

VEGF-R1

66/4 (5.7%)^a

65/66 (98.5)

1

1 (1.4%)

2.14 (0.27–16.98)

10 (14.3%)

1.33 (0.18–10.0)

23 (32.9%)

0.94 (0.13–6.96)

32 (45.7%)

VEGF-R2

64/6 (8.6%)^a

63/64 (98.4)

1

1 (1.4%)

1.04 (0.13–8.61)

7 (10.0%)

1.24 (0.16–9.94)

10 (14.3%)

1.29 (0.18–9.42)

46 (65.7%)

VEGF-R3

50/20 (28.6%)^a

49/50 (98.0)

1

1 (1.4%)

0.81 (0.07–9.01)

3 (4.3%)

1.27 (0.17–9.56)

20 (28.6%)

1.07 (0.14–8.03)

26 (37.1%)